◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Krishna Institute of Medical Sciences Limited (KIMS) Revenue 2022–2026

Name: Krishna Institute of Medical Sciences Limited (KIMS) revenue history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Krishna Institute of Medical Sciences Limited annual revenue for fiscal 2026 was ₹38.7 billion, an increase of 28.9% from ₹30.0 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

KIMS Annual Revenue

Revenue (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹38.7B	₹30.0B	₹24.7B	₹21.7B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KIMS Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹11.8B	₹10.7B	₹10.0B	₹9.6B	₹8.7B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

FORTIS Revenue — Fortis Healthcare Limited
ASTERDM Revenue — Aster DM Quality Care Limited
MEDANTA Revenue — Global Health Limited
NH Revenue — Narayana Hrudayalaya Limited
BDMS Revenue — Bangkok Dusit Medical Services Public Company Limited

More KIMS metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All KIMS financial statements → Interactive KIMS charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.